ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Clinical trials for ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced breast cancer: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial is testing a new drug called palazestrant (OP-1250) combined with ribociclib against the standard letrozole plus ribociclib for people with ER+, HER2- advanced breast cancer who haven't had prior treatment. About 1,000 participants will be randomly assigned to …
Matched conditions: ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo trial hopes to tame advanced breast cancer
Disease control Recruiting nowThis study tests two experimental drugs, camizestrant and atirmociclib, in 24 people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has worsened after prior treatment. The main goal is to check safety and how the body processes the drugs, with ea…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC